MedTrace Logo

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

NCT04217733 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-01-03

No results posted yet for this study

Summary

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome

Conditions

  • IBS - Irritable Bowel Syndrome

Interventions

DRUG

pentoxyifylline

Pentoxyifylline two times daily for 3 months

DRUG

Mebeverine

Mebeverine 3 times for 3 months

DRUG

ethosuximide

ethosuximide 3 times for 3 months

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Mostafa Mahmoud Bahaa El dien, Msc · Clinical Pharmacy department

  • Sahar El-Haggar, Prof · Clinical pharmacy Department- Tanta University

  • Sahar Hegazy, Prof. · Clinical pharmacy Department- Tanta University

  • Sherief Abd-Elsalam, Ass. Prof. · Tropical Medicine Department- Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2030-12-01
Completion
2030-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217733 on ClinicalTrials.gov